Anthony
Preliminary Results Show TAE Life Sciences’ TC440 Boron-Containing Drug Holds Promise for Revolutionizing Cancer Treatment Strategies
Preliminary Results Show TAE Life Sciences’ Novel Boron-Containing Drug Holds Promise for Revolutionizing Boron Neutron Capture Therapy
TAE Life Sciences, a pioneering company in the field of cancer treatment, today announces the results from early testing of its TC440 boron-containing dipeptide compound for Boron Neutron Capture Therapy (BNCT).
Leading Cancer Center in Poland Announce Plans for a New State-of-the-Art BNCT Facility
TAE Life Sciences, a global leader in advanced biological-targeted radiation therapy, and creator of next-genera on boron neutron capture therapy (BNCT) systems, and the Franciszek Łukaszczyk Oncology Center (FLOC)
TAE Life Sciences Announces First Cancer Patient Treatments Using Accelerator-Based Biologically Targeted Radiation Therapy (BNCT)
TLS and Avita Biomedical Announce Strategic Partnership
TLS Announces Partnership with HDX for BNCT in South Korea
TAE Life Sciences Sponsored Study Details Results of Proton Boron Fusion Therapy Biological Effectiveness
TAE Life Sciences to Sponsor Industry Expert Theater “New Era in Biologically-Targeted Radiation Therapy” at 2021 ASTRO Annual Meeting
Have questions about BNCT? Get answers on our new BNCT Forum